Celcuity Inc.

Celcuity Inc. is a commercial-stage biopharmaceutical company focused on targeted cancer therapies involving the PI3K/AKT/mTOR (PAM) pathway. Its lead medicine, REVTORPYK™ (gedatolisib), is FDA-approved for a specified second-line advanced breast cancer setting. The company is also evaluating gedatolisib in clinical trials for breast cancer, prostate cancer, and other solid tumors.